Sinterx Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 0.75 M
as on 13-12-2024
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 172.73%
(FY 2023)
- Profit 226.91%
(FY 2023)
- Ebitda 222.64%
(FY 2023)
- Net Worth 266.40%
(FY 2023)
- Total Assets 48.03%
(FY 2023)
About Sinterx Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M, as per Ministry of Corporate Affairs (MCA) records.
Sruthi Medapati, Deepika Punnapu, and Golla Padmavathi serve as directors at the Company.
- CIN/LLPIN
U24299TG2021PTC154397
- Company No.
154397
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sinterx Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sruthi Medapati  | Director | 26-Aug-2021 | Current |
| Deepika Punnapu | Director | 26-Aug-2022 | Current |
| Golla Padmavathi | Director | 01-Dec-2021 | Current |
Financial Performance of Sinterx Pharma.
Sinterx Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 172.73% increase. The company also saw a substantial improvement in profitability, with a 226.91% increase in profit. The company's net worth Soared by an impressive increase of 266.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sinterx Pharma?
Unlock access to Sinterx Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Yashashree Syndicate Private LimitedActive 2 years 7 monthsSruthi Medapati and Golla Padmavathi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sinterx Pharma?
Sinterx Pharma has a workforce of 12 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sinterx Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sinterx Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
